.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,366,734

« Back to Dashboard

Claims for Patent: 5,366,734

Title: Continuous release pharmaceutical compositions
Abstract:Pharmaceutical compositions, comprising a polylactide and a pharmacologically active, acid stable polypeptide, which when placed in an aqueous physiological environment release the polypeptide at an approximately constant rate in an essentially monophasic manner, with a minimal, or no induction period prior to the release; polylactides suitable for use in said compositions; and a method for the manufacture of such polylactides.
Inventor(s): Hutchinson; Francis G. (Lymm, GB)
Assignee: Zeneca Limited (London, GB2)
Application Number:07/751,584
Patent Claims: 1. A method for continuously administering a pharmaceutically active peptide to a subject in need of such administration which comprises:

(1) providing an implantable or injectable composition consisting essentially of (a) from 50% to 99.999% of a polylactide which is a polymer of lactic acid alone, a copolymer of lactic acid and glycolic acid wherein the ratio of glycolide to lactide units is from 0 up to 3:1, a mixture of such polymers, a mixture of such copolymers, or a mixture of such polymers and copolymers, the lactic acid being either in racemic or in optically active form, and such polylactide being either soluble in benzene and having an inherent viscosity of from 0.093 (1 g. per 100 ml. in chloroform) to 0.5 (1 g. per 100 ml. in benzene), or insoluble in benzene and having an inherent viscosity of from 0.093 (1 g. per 100 ml in chloroform) to 4 (1 g. per 100 ml in chloroform or dioxan), and (b) from 0.001% to 50% of a pharmacologically active polypeptide which has a molecular weight of at least about the same as the molecular weight of tetragastrin, which is not significantly hydrolyzed under the conditions encountered within the composition during the period of use envisioned, and which contains four or more amino acid residues, said polypeptide being dispersed in said polylactide so that some of the said polypeptide is present at the external surface of the composition, which composition, when placed in an aqueous physiological-type environment absorbs water and exhibits two successive phases of release of polypeptide, the first phase being release by initial diffusion through aqueous polypeptide domains communicating with the exterior surface of the composition, and the second phase being release consequent upon degradation of the polylactide, characterized in that the diffusion phase and the degradation-induced phase overlap in time, said composition being further characterized by the fact that, when placed in an aqueous physiological type environment, water diffuses into the matrix and is partitioned between polypeptide and polylactide to form aqueous polypeptide domains, the said domains increasing with increasing absorption of water until the continuity of the said domains reaches a sufficient level to communicate with the exterior surface of the composition, whereupon polypeptide starts to be released from said composition by diffusion through aqueous polypeptide channels formed from said domains, which second phase continues until substantially all of the remaining polypeptide is released over at least a week;

(2) implanting or injecting said composition into the body of said subject, so that the composition releases said peptide initially by leaching from the surface of said composition and also by absorption of water into said composition, which results in (a) the formation of aqueous peptide solution, (b) the formation of aqueous channels in the composition through which said aqueous peptide solution diffuses into the subject body, and (c) ultimately, the complete degradation of the polylactide; and

(3) permitting such release to proceed continuously over a period of at least one week until said composition is completely utilized for the intended treatment wherein said release is not biphasic or discontinuous.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc